News
The Canadian pharmaceutical industry is still waiting to learn about tariffs as high as 200 per cent on exports to the U.S.
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 ...
Indian pharmaceutical industry leaders strongly criticize U.S. President Trump's tariff announcement, arguing it will harm ...
Nine of the groups that signed the letter have received funding from PhRMA, the primary trade organization representing the pharmaceutical industry.
Analysts anticipate Biomarin Pharmaceutical to report an earnings per share (EPS) of $0.93. The market awaits Biomarin ...
24/7 Wall St. on MSN5d
4 High-Yield Blue-Chip Pharmaceutical Giants Offer Huge Total Return PotentialHere are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.
The 15 percent tariff rate agreed under the new deal could significantly impact pharma firms reliant on European imports.
The pharmaceutical sector, a beacon of innovation, stands tall in Europe's economic landscape. Yet even a robust industry is not immune to financial challenges.
Iraq's drug localization efforts save $1B annually, with 34 factories at full capacity & 178 new applications, says PM's ...
Evolving trade policies and tariffs strain bio/pharmaceutical manufacturers, affecting profits and operational strategies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback